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We describe the spread of a dengue virus during an
outbreak in Saint Martin island (French West Indies) during
winter 2003–2004. Dengue type 3 viruses were isolated
from 6 patients exhibiting clinical symptoms. This serotype
had not been detected on the island during the preceding 3
years. Genome sequence determinations and analyses
showed a common origin with dengue type 3 viruses iso-
lated in Martinique 2 years earlier.
D
engue virus (DENV) infection is recognized as a
major public health problem; >50 million persons are
infected each year worldwide (1), and the incidence of
severe, sometimes lethal, forms of the disease is increasing
(2). Dengue viruses are mosquitoborne flaviviruses with a
single-stranded, nonsegmented, positive-sense RNA
genome  ≈11 kb in length. Four antigenically distinct
serotypes, DENV types 1 to 4, exist (3). Infection with any
serotype can lead to disease, ranging from mild infection,
dengue fever (a generally mild disease with complete
recovery), to severe forms (dengue hemorrhagic fever and
dengue shock syndrome). Molecular epidemiologic studies
have investigated the possibility of a link between particu-
lar DENV genotypes or clusters and particular clinical
forms of disease (4,5). Consequently, finding new viral
genotypes in areas where they had been absent could be of
epidemiologic and clinical interest. A recent work
described the emergence and the global spread of
DENV-3 subtype III (5). Originating from the Sri
Lankan/Indian subcontinent, the new variant likely spread
to eastern Africa in the 1980s, then to Latin America in the
mid-1990s (5). Previous work in our laboratory identified
a DENV-3 subtype 3 of the same origin in Martinique in
1999 (6).
Whereas other Caribbean islands had annual dengue
epidemics, the last outbreak reported in Saint Martin
(French West Indies) (Figure 1) was in 1977 (7). Only
DENV-1 was isolated during this epidemic, while
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Figure 1. Map of Saint Martin, an island in the Caribbean. The
lower map represents the Caribbean subregion. The year of
dengue virus type 3 subtype III detection is indicated under the
concerned island or country. The upper map is a close-up of Saint
Martin. Source: Centre de documentation de l’Institut de Médecine
Tropicale du Service de Santé des Armées.DENV-1, DENV-2, and DENV-3 circulated in Puerto Rico
at the same time (8). In 2000, during an interepidemic peri-
od, 1 isolate of DENV-3 was reported in Saint Martin
(http://www.carec.org/annrep00/index.html), but to our
knowledge its sequence was not determined. During the
last 3 years, no further DENV isolates have been reported
on the island. However, in December 2003, an outbreak of
febrile illness was reported after heavy rains. An estimated
108 persons were infected, and DENV was suspected to be
the causative agent by Saint Martin Lepers Laboratory (9).
During this period, blood samples collected at early and
late stages of infections were examined at the Tropical
Medicine Institute of the French Armed Forces Medical
Service (Institut de Médecine Tropicale du Service de
Santé des Armées [IMTSSA]) tropical virology laboratory
in Marseille to identify the etiologic agent. DENV-3 was
isolated on C6/36 cells (Aedes albopictus). Partial genom-
ic sequences were determined for each isolated virus to
evaluate the origin and diversity of its spread. This
approach should help clarify the geographic distribution of
isolates in the Caribbean islands as well as the virus’circu-
lation in and transmission to humans.
Materials and Methods
The Outbreak 
In December 2003, an outbreak of febrile illness was
reported (9) after heavy rainfalls in Saint Martin (29,000
inhabitants in the French part and 36,000 in the Dutch
part). The outbreak seemed to start first in the northeastern
part of the island (“Baie orientale” and “Cul de sac” neigh-
borhoods), then spread through the island (Figure 1). The
temporal distribution of the outbreak is shown in Figure 2
(10). We used a commercial enzyme-linked immunosor-
bent assay (ELISA) (Eurobio, Courtaboeuf, France) in
Saint Martin Lepers Laboratory to determine that, from
October 2003 to April 2004, a total of 108 persons were
infected; a DENV was suspected as the etiologic agent
(10). Twelve persons manifesting thrombocytopenia with-
out hemorrhagic signs were hospitalized (9).
Collection and Transport of Samples
Sera from 26 patients with dengue-like syndromes were
collected at a local laboratory and transported (by air, at
4°C) to the IMTSSA laboratory in Marseille for serologic
diagnosis and etiologic agent identification. All these sam-
ples were collected from December 2003 to January 2004,
the peak of the outbreak.
Serologic Diagnosis
In-house immunoglobulin (Ig) M-capture enzyme
immunoassays (MAC-ELISA) and IgG sandwich ELISA
were used to detect serum IgM and IgG antibodies to
Toscana virus, dengue viruses, West Nile virus, and St.
Louis encephalitis virus. Briefly, IgM antibodies were
captured with rabbit anti-human IgM antibodies (Interchim,
Montluçon, France). Toscana, dengue, West Nile, and Saint
Louis antigens, prepared on Vero cells and inactivated by
betapropiolactone (Sigma-Aldrich, St Quentin Fallavier,
France), were added. Specific binding was demonstrated by
using a Toscana virus, dengue viruses, West Nile virus, and
St. Louis encephalitis virus mouse hyperimmune ascitic
fluid virus (11) and a goat anti-mouse peroxidase-labeled
conjugate (Interchim). For IgG detection, antibodies to
Toscana virus, dengue viruses, West Nile virus, and St.
Louis encephalitis virus were captured by goat anti-mouse
IgG antibodies; viral antigens were followed by test sera;
and specific binding was demonstrated by using a peroxi-
dase-labeled goat anti-human IgG conjugate. Serum
samples were considered positive if the optical density at
450 nm was >3-fold the mean of negative sera with an
OPTImax spectrophotometer (Molecular Devices, Saint
Gregoire, France).
Virus Isolation and Propagation
Work with the infectious virus was carried out in a
biosafety level 3 laboratory. Virus isolation was attempted
when the first sample could be collected <5 days after
onset of illness and when enough serum was collected for
serologic analysis (12). DENV-3 strains (see Online
Appendix, available from http://www.cdc.gov/ncidod/
EID/vol11no05/04-0959_app.htm) were all isolated from
leukocytes of patients. Leukocytes of the samples were
directly coincubated with C6/36 cells (Ae. albopictus)
grown at 28°C in Leibowitz’s L15 medium (BioWhittaker
Europe, Verniers, Belgium) supplemented with 1% L-glu-
tamine and 2% tryptose phosphate broth. Fetal bovine
serum (5% final) was added 1 h later. Supernatants were
collected on day 5 after infection.
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Figure 2. Temporal distribution of the outbreak (adapted from [10]).
Bars indicate the suspected dengue patients observed by sentinel
physicians; dark squares (curve) indicate laboratory-confirmed
cases.Indirect immunofluorescence (IF) was performed on
C6/36 cells with DENV-1, -2, -3, and -4 serotype–specific
monoclonal antibodies (kindly provided by Nick
Karabatsos, Centers for Disease Control and Prevention,
Fort Collins, Colorado); on mouse hyperimmune ascitic
fluids for West Nile virus and Bunyamwera virus; and on
grouping fluids for alphaviruses, phleboviruses, and
California serogroup viruses. After isolation attempts,
remaining sera were used for serologic studies but not for
DENV-3–specific reverse transcription–polymerase chain
reaction (RT-PCR) because too little serum was available
after serologic tests.
RNA Preparation and cDNA Synthesis
Viral RNA was extracted from 200-µL aliquots of
infected cells supernatants by using the High Pure Viral
RNA kit (Roche Diagnostics, Meylan, France) following
manufacturer’s protocol. Two overlapping viral cDNA
fragments were generated by RT with Superscript II
reverse transcriptase (Invitrogen/Life Technologies, Cergy
Pontoise, France) according to the manufacturer protocols
with D3/C/863/18 and D3/C/1419/18 primers (Table).
Specific primers (Table) designed from the nucleotide
sequence of the reference DENV-3 H87 (GenBank acces-
sion no. L11423) (13) were used for PCR amplification by
using AmpliTaq DNA Gold (Applera, Courtaboeuf,
France). 
DNA Sequencing
PCR products were purified from 1.5 % agarose gels,
by using the QIAquick gel extraction kit (Qiagen,
Courtaboeuf, France) and directly sequenced with the
direct and reverse primers (Table) and the Big Dye
Sequencing kit (Applera). Sequencing was carried out with
an automatic sequence analyzer (ABI PRISM 3100,
Applera) following the manufacturer’s protocol. 
Sequences of the Saint Martin DENV isolates were
compared to GenBank database DENV sequences (com-
plete list in Online Appendix). Alignments of nucleotide
and amino acid sequences of the prM/M and partial E
nucleotide sequences (nucleotide numbers 437–1144 by
reference to the sequence of the D3H87 strain) were per-
formed with ClustalW1.7 software (14). Phylograms were
constructed with the MEGA 2 program (15), and tree
drawing used the Jukes-Cantor algorithm for genetic dis-
tance determination and the Neighbor Joining method. The
robustness of the resulting tree was tested by 1,000 boot-
strap replications.
Results and Discussion
From October 2003 to April 2004, DENV-3 circulated
on the island, and 108 cases of dengue fever were serolog-
ically or virologically confirmed in both the Lepers
Laboratory and the IMTSSA laboratory, and 12 persons
were hospitalized (10). If one takes into account the 180
suspected cases observed during this period, the incidence
of dengue fever during the epidemic was ≈0.62%
(180/29,000) on the French part of the island; this value
was consistent with values already observed in the
Caribbean region (http://www.carec.org/data/dengue/
1998/table2.html). No data were available from the Dutch
half. 
During this period, an additional 26 blood samples from
patients with dengue-like syndromes at early stage of the
infection were received in IMTSSA Tropical Virology
Laboratory in Marseille. Among them, 13 were positive for
dengue infection by presence of IgM, elevation (4-fold) of
specific IgG, or both. Virus was isolated from 6 other
patients, and DENV-3 was identified by IF using serotype-
specific monoclonal antibodies. No fluorescence was
observed when DENV-1, DENV-2, or DENV-4 monoclonal
antibodies were used. Moreover, IF tests were negative
when antibody to West Nile virus, Toscana virus, Bunyam-
wera virus, alphaviruses, phleboviruses and California
serogroup viruses was used. These cases were considered
confirmed dengue fever; all the patients recovered fully. 
DENV-3 was genetically identified in the 6 IF positive
isolates (D3StMart1–D3StMart6, referred to as GenBank
accession no. AY750713–AY750718) by using BLAST-
NCBI software. Comparison of partial sequences showed
a high degree of identity between the strains isolated from
patients on Saint Martin: paired identity at the nucleotide
level ranged from 99.3% to 100%. When compared to
00PuertoR1 strain of the Latin American cluster defined by
Messer (5), the values were 99.5%–99.6%. Nucleotide
comparison gave the following values: 98.3%–98.4% for
East African cluster (5), 98.8%–98.9% for Group B (5),
and 96.8%–96.9% for Group A (5). This comparison indi-
cated a close relationship between Saint Martin and Latin
American isolates.
The strains from Saint Martin shared an 11-nucleotide
insertion between position 10,275 and position 10,276 in
the 3′UTR (AGTGAAAAAGA). The same insertion was
found in isolates from Martinique 2 years earlier (6) and
from DENV-3 Sri Lanka (6), indicating a probable com-
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Lankan origin for DENV-3 subtype III circulating in the
Latin American and Caribbean regions (5) and with exten-
sion of the virus from a single importation event.
A phylogenetic tree was constructed based on partial
sequences of the prM/M-E gene region (position
437–1144) of the genomes, including the strains from
Saint Martin and several other previously characterized
strains from different origins (16–19). DENV isolated
from Saint Martin was grouped in subtype III, as defined
by Lanciotti (17) (data not shown). Another phylogenetic
tree was constructed with the strains analyzed by Messer
(5) (Figure 3). Despite the high overall similarity of the
subtype III sequences, distinct groups could be distin-
guished. The 6 isolates from Saint Martin clustered
together. The small lineage difference of D3StMart2 is
supported by a 95-bootstrap value, but no evidence sug-
gests that such difference implies multiple introductions
or a longer transmission period. However, Saint Martin
DENV-3 fell in the Latin American cluster defined by
Messer (5), which also includes isolates from Guatemala,
Nicaragua, and Mexico. Isolates from Saint Martin were
particularly close to Martinique isolates (6) and the
00PuertoR1 isolate, which were the geographically and
temporally closest isolates of the cluster. The analysis of
the deduced amino acid sequences generated a similar
phylogram. Altogether, these results indicate that the Saint
Martin viral isolate belongs to the genotype Puerto Rico
2000 previously reported (5). These results also confirm a
common origin for all DENV-3 circulating in the
Caribbean and Latin American region; their ancestor
probably originated from Sri Lanka. Additional American
DENV-3 strain sequences, encompassing the insertion
site, should help to confirm this hypothesis.
The question arose whether the introduction from Sri
Lanka was a single event in the Latin American region,
first appearing in Panama (5), then spreading through the
Caribbean subregion and South America. In fact, viruses
belonging to subtype III were first reported in Nicaragua
and Panama in 1994 (20). They were then identified in
Guatemala from 1996 to 1998; in Puerto Rico, Barbados,
and Jamaica in 1998 (18); and in Martinique in 1999 (6).
The introduction of DENV-3 in Saint Martin was reported
in 2000 (http://www.carec.org/annrep00/index.html), but
the subtype was not determined. No virus isolation was
reported for 3 years, until the viruses we characterized
were isolated. The rapid extension of DENV-3 belonging
to subtype III, which have almost completely replaced
preexisting DENV of serotype 1 and 2, is indicative that
these particular viruses have adapted to Caribbean and
Latin American conditions. Together with previous
studies (5,6), identification of viruses belonging to sub-
type III in another area of the Caribbean region confirms
the remarkable epidemiologic success of this particular
lineage of dengue viruses.
Comparable substitution of local DENV by a new
genotype was previously described in the Caribbean
region (12). New viruses, often originating from Southeast
Asia, arise as successive waves, replacing previous ones.
In this regard, sampling of DENV-3 subtype III virus
nucleotide sequences from all countries in the Caribbean
and the peri-Caribbean area need to be expanded so that
we can understand DENV circulation in the region.
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Figure. 3. Phylogenetic tree of dengue type 3 subtype III viruses,
based on prM/M and partial E nucleotide sequences (nucleotide
numbers 437 to 1144) available in GenBank database.
Phylograms were constructed with the MEGA 2 program (15),
using the Jukes-Cantor algorithm and the neighbor joining
method. The percentage of successful bootstrap replicates (1,000
bootstrap replications, confidence probability  90%) is indicated at
nodes. The length of branches is proportional to the number of
nucleotide changes (percentage of divergence). The strains
sequenced in this work are underlined. Dark triangles correspond
to viruses of the same group clustering together; dots indicate a
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